scientific abstract submission rules

Call for Abstracts 

Med-In Pharma 2022 Conference | 17 and 18 November 2022 – DEADLINE EXTENDED TO 04/11/2022

Members of the scientific community practicing in the field of medicine, surgery, dentistry, pharmacy and applied sciences are invited to prepare abstracts related to innovative techniques in medicine, surgery and dentistry enabling technologies, smart factory and future trends in pharmacy and applied sciences for submission to the scientific committee of the Med-In Pharma 2022 Conference. Abstracts which have been accepted by the scientific committee may be presented as a poster. Submissions considered to be of high quality may be selected for an oral communication. Participants are invited to submit abstracts by e-mail to [email protected] The deadline has been extended to 04/11/2022/.

Authors will be notified on the final results of the review process by  8 th November 2022.  Accepted abstracts are to be presented by one of the authors who must register for the Malta Med-Tech World Summit 2022. Presenting authors should be registered for the conference by  11 th November 2022. For further information, please contact [email protected]. 

Abstract Submission Guidelines 

All abstracts must be prepared according to the instructions below.  

Abstracts must not exceed 300 words and should not include any tables or figures.  Abstract text must be in Times New Roman font, 12-point, single spacing and justified text. Abbreviations should be kept to a minimum and placed in parentheses after the full term appears for the first time. Linguistic accuracy is the responsibility of the authors. Drug products mentioned in the abstract should be identified by their non-proprietary names only. Any possible conflict of interest shall be declared. 

Text should be presented as follows: 

Background and Objective
Setting and Method
Literature References: Optional these must be included in the 300-word limit

Individuals may submit any number of abstracts as first author and/or appear on any number of abstracts as a co-author. You should only submit an abstract if the first author is able to and intends to attend the event to present the poster. Presentations must clearly relate to the abstract as submitted and the research described (where appropriate). Once an abstract has been accepted, if circumstances arise that prevent the first author from presenting you must inform us.

  • the content will likely be of interest to an adequate number of delegates  
  • the abstract is written so as to be understandable to delegates who may not have a research background; 
  • the significance of the poster outcome is clearly stated in the abstract; 
  • the methods appear to be adequate 
  • the results of the study are described in adequate detail and the conclusions in the abstract appear to be justified by the results presented. 
  • the abstract questions or potentially challenges conventional practice, through the uniqueness of the scenario or its outcome; 
  • the abstract highlights new information, or a unique treatment or management process, clinical governance structure or service delivery model; 

On submission of the abstract, the first named author must ensure that he/she has the approval and a copyright assignment from any other authors and contributors involved in the work.

Judges appointed will assess and judge scientific abstracts for poster presentations. To avoid any conflict of interest, a “blind” review process will be used. The decision is final.

Supported by

keep updated. subscribe to our newsletter.